Severity: Warning
Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 197
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 197
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 271
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3165
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 597
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 511
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 317
Function: require_once
98%
921
2 minutes
20
The dysregulation of mitochondrial homeostasis in tumor cells plays a significant role in tumorigenesis and progression. Mitochondria within tumor cells exhibit extensive mutations, proliferation, and fragmentation to accommodate heightened metabolic and energy requirements. This disruption of mitochondrial homeostasis is intricately linked to tumor cell proliferation, invasion, metastasis, energy metabolism, and redox balance. Disrupting the homeostasis of mitochondria in tumor cells has emerged as a novel approach in the clinical management of tumors, with mitochondria-targeted pharmaceuticals showing promise as a potential breakthrough in tumor therapy. This review outlines recent advancements in the understanding of mitochondrial homeostatic dysregulation in oncology and discusses the potential of targeting oncogenic mitochondria as a novel therapeutic avenue for the treatment of tumors.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.critrevonc.2025.104899 | DOI Listing |